Table 4.

HRs with 95% CIs comparing all-cause mortality between AHCT and non-AHCT treated stage IB⁺ MCL patients diagnosed between January 2000 and June 2014 aged up to 65 y at diagnosis, who were alive 6 mo after diagnosis when follow-up started (n = 363)

		HR* (95% CI)	HR† (95% CI)
Age at diagnosis	AHCT	(n = 363)	(n = 342)
All ages‡	Yes	0.45 (0.32-0.63)	0.58 (0.40-0.85)
	No	1.00	1.00
≤49 y	Yes	0.43 (0.14-1.35)	0.38 (0.12-1.19)
	No	1.00	1.00
50 to 59 y	Yes	0.47 (0.26-0.86)	0.55 (0.29-1.02)
	No	1.00	1.00
60 to 65 y	Yes	0.53 (0.34-0.84)	0.70 (0.43-1.14)
	No	1.00	1.00

Follow-up was restricted to the first 10 y after diagnosis.

^*From a Cox proportional hazards model treating AHCT as a time-varying exposure (for age-stratified results, an interaction between AHCT and age at diagnosis was included).

^†From a Cox proportional hazards model as above, adjusted for calendar year of diagnosis (as a restricted cubic spline), sex, civil status, educational level, CCI, stage, and performance status.

^‡A nonsignificant interaction with AHCT and age was seen, indicating that the association between AHCT and all-cause mortality was similar between age groups.